🚀 VC round data is live in beta, check it out!
Sionna Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sionna Therapeutics and similar public comparables like Oruka Therapeutics, Everest Medicines, Agios Pharmaceuticals, Novavax and more.
Sionna Therapeutics Overview
About Sionna Therapeutics
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Founded
2019
HQ
Employees
41
Website
Sectors
Financials (LTM)
EV
$1B
Sionna Therapeutics Financials
Sionna Therapeutics reported last 12-month revenue of — and negative EBITDA of ($95M).
In the same LTM period, Sionna Therapeutics generated — in gross profit, ($95M) in EBITDA losses, and had net loss of ($82M).
Revenue (LTM)
Sionna Therapeutics P&L
In the most recent fiscal year, Sionna Therapeutics reported revenue of — and EBITDA of ($88M).
Sionna Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($95M) | XXX | ($88M) | XXX | XXX | XXX |
| Net Profit | ($82M) | XXX | ($75M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sionna Therapeutics Stock Performance
Sionna Therapeutics has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Sionna Therapeutics' stock price is $36.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $-1.69 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSionna Therapeutics Valuation Multiples
Sionna Therapeutics trades at (14.6x) EV/EBITDA.
Sionna Therapeutics Financial Valuation Multiples
As of March 21, 2026, Sionna Therapeutics has market cap of $2B and EV of $1B.
Equity research analysts estimate Sionna Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sionna Therapeutics has a P/E ratio of (19.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/EBITDA | (14.6x) | XXX | (15.8x) | XXX | XXX | XXX |
| EV/EBIT | (14.6x) | XXX | (15.6x) | XXX | XXX | XXX |
| P/E | (19.8x) | XXX | (21.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (20.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sionna Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sionna Therapeutics Margins & Growth Rates
Sionna Therapeutics' revenue in the last fiscal year grew by —.
Sionna Therapeutics' revenue per employee in the last FY averaged $0.0M.
Sionna Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 29% | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sionna Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Oruka Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Everest Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Agios Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Novavax | XXX | XXX | XXX | XXX | XXX | XXX |
| Nurix Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sionna Therapeutics M&A Activity
Sionna Therapeutics acquired XXX companies to date.
Last acquisition by Sionna Therapeutics was on XXXXXXXX, XXXXX. Sionna Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sionna Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSionna Therapeutics Investment Activity
Sionna Therapeutics invested in XXX companies to date.
Sionna Therapeutics made its latest investment on XXXXXXXX, XXXXX. Sionna Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sionna Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sionna Therapeutics
| When was Sionna Therapeutics founded? | Sionna Therapeutics was founded in 2019. |
| Where is Sionna Therapeutics headquartered? | Sionna Therapeutics is headquartered in United States. |
| How many employees does Sionna Therapeutics have? | As of today, Sionna Therapeutics has over 41 employees. |
| Who is the CEO of Sionna Therapeutics? | Sionna Therapeutics' CEO is Michael Cloonan. |
| Is Sionna Therapeutics publicly listed? | Yes, Sionna Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Sionna Therapeutics? | Sionna Therapeutics trades under SION ticker. |
| When did Sionna Therapeutics go public? | Sionna Therapeutics went public in 2025. |
| Who are competitors of Sionna Therapeutics? | Sionna Therapeutics main competitors are Oruka Therapeutics, Everest Medicines, Agios Pharmaceuticals, Novavax. |
| What is the current market cap of Sionna Therapeutics? | Sionna Therapeutics' current market cap is $2B. |
| Is Sionna Therapeutics profitable? | No, Sionna Therapeutics is not profitable. |
| What is the current EBITDA of Sionna Therapeutics? | Sionna Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Sionna Therapeutics? | Current EBITDA multiple of Sionna Therapeutics is (14.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.